Novel SLC39A4 mutation in acrodermatitis enteropathica

Pediatr Dermatol. 2011 Nov-Dec;28(6):697-700. doi: 10.1111/j.1525-1470.2011.01637.x.

Abstract

Acrodermatitis enteropathica (AE) is a rare autosomal-recessive disorder characterized by dermatitis, alopecia, diarrhea, and retardation of growth and development. AE maps to 8q24.3 and is associated with mutations in the intestinal zinc transporter ZIP4 encoded by the gene SLC39A4. We describe a novel homozygous mutation, 1191insC, in SLC39A4 in a patient from Sierra Leone and suggest that AE should be considered within the differential diagnosis for acrodermatitis in children from Sierra Leone. Genetic testing for this founder mutation can be easily performed for this treatable disorder.

Publication types

  • Case Reports

MeSH terms

  • Acrodermatitis / drug therapy
  • Acrodermatitis / genetics*
  • Alopecia / drug therapy
  • Alopecia / genetics
  • Cation Transport Proteins / genetics*
  • Diarrhea / drug therapy
  • Diarrhea / genetics
  • Dietary Supplements
  • Failure to Thrive / diagnosis
  • Failure to Thrive / genetics
  • Female
  • Homozygote
  • Humans
  • Infant
  • Mutation*
  • Treatment Outcome
  • Zinc / blood
  • Zinc / deficiency
  • Zinc Sulfate / therapeutic use

Substances

  • Cation Transport Proteins
  • SLC39A4 protein, human
  • Zinc Sulfate
  • Zinc

Supplementary concepts

  • Acrodermatitis enteropathica